Loading...
Building better monoclonal antibody-based therapeutics
For 20 years, monoclonal antibodies (mAbs) have been a standard component of cancer therapy, yet there is still much room for improvement. Efforts continue to build better cancer therapeutics based on mAbs. Anti-cancer mAbs function via a variety of mechanisms including directly targeting the malign...
Na minha lista:
| Udgivet i: | Nat Rev Cancer |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4491443/ https://ncbi.nlm.nih.gov/pubmed/25998715 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrc3930 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|